Identifying Electronic Nicotine Delivery System Brands and Flavors on Instagram: Natural Language Processing Analysis

Autor: Rob Chew, Michael Wenger, Jamie Guillory, James Nonnemaker, Annice Kim

Publikováno v: Journal of Medical Internet Research, Vol 24, Iss 1, p e30257 (2022)

BackgroundElectronic nicotine delivery system (ENDS) brands, such as JUUL, used social media as a key component of their marketing strategy, which led to massive sales growth from 2015 to 2018. During this time, ENDS use rapidly increased among youth

Externí odkaz: https://doaj.org/article/ac6224a508df4b1aaafd9c835db0e36b

Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study

Autor: Andrea Knapp, Tarec Christoffer El-Galaly, Michael Wenger, Judith Trotman, Michel Meignan, Tina Nielsen, Farheen Mir, Lale Kostakoglu, Sally F. Barrington, Denis Sahin

Publikováno v: J Nucl Med
Barrington, S F, Mir, F, El-Galaly, T C, Knapp, A, Nielsen, T G, Sahin, D, Wenger, M, Kostakoglu, L, Trotman, J & Meignan, M 2022, ' Follicular lymphoma treated with first-line immunochemotherapy : A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study ', Journal of Nuclear Medicine, vol. 63, no. 8, pp. 1149-1154 . https://doi.org/10.2967/jnumed.121.262869

Complete metabolic response (CMR) on positron emission tomography-computed tomography (PET-CT) was the sole independent predictor of overall survival in the PET sub-study of the phase III GALLIUM trial (NCT01332968) in first-line treatment of high tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08bd21a124412ee56418388672fe9ef9
https://doi.org/10.2967/jnumed.121.262869

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

Autor: Guillaume Cartron, Florence Hourcade-Potelleret, Franck Morschhauser, Gilles Salles, Michael Wenger, Anna Truppel-Hartmann, David J. Carlile

Publikováno v: Haematologica, Vol 101, Iss 2 (2016)

Obinutuzumab (GA101) is a type II, glycoengineered anti-CD20 monoclonal antibody for the treatment of hematologic malignancies. Obinutuzumab has mechanisms of action that are distinct from those of rituximab, potentially translating into improved cli

Externí odkaz: https://doaj.org/article/2c7b09845b494e74b826aa817e609518

Public safety assessment

Autor: Matthew DeMichele, Peter Baumgartner, Megan Comfort, Michael Wenger, Kelle Barrick

Publikováno v: Criminology & Public Policy. 19:409-431

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::62f75359c002228068336ad490117a99
https://doi.org/10.1111/1745-9133.12481

Where’s the Bias: No Evidence of Bias by Sex When Testing the Public Safety Assessment

Autor: Matthew DeMichele, Peter Baumgartner, Michael Wenger, Megan Comfort, Amanda Witwer

Publikováno v: Crime & Delinquency. :001112872211309

Pretrial assessments are criticized for inherent biases. We conduct research in Kentucky to assess the predictive validity and differential prediction by sex of one pretrial assessment, the Public Safety Assessment (PSA). Our research is unique becau

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::622ff66fda7cea42f5b717084204c980
https://doi.org/10.1177/00111287221130953